Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Antibodies specific to IL-17A and IL-17F
US9045537B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9045537-B2 |
| Application number | US-201414173613-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 5, 2014 |
| Priority date | Apr 23, 2008 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
First claim
Opening claim text (preview).
What is claimed is: 1. A monoclonal antibody that specifically binds an epitope of human IL-17F, wherein the epitope comprises residues GLN71, CYS72, ILE86, ASN89, SER90 and VAL128 of SEQ ID NO:22 and wherein the monoclonal antibody additionally binds IL-17A. 2. The antibody of claim 1 , wherein the epitope comprises residues GLN71, CYS72, ASN74, LEU75, ILE86, ASN89, SER90, PRO92, VAL128, HIS131 and GLN133 of SEQ ID NO:22. 3. The antibody of…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C07K16/244Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9045537B2 cover?
- The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
- Who is the assignee on this patent?
- Ucb Pharma Sa, Ucb Pharma Sa
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).